John D Lambris

InstitutionUniversity of Pennsylvania
AddressPhiladelphia
Pennsylvania
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 9 Covid-19 publications, with a maximum of 2 publications in April 2020
    All Publications
    Bar chart showing 316 publications over 20 distinct years, with a maximum of 24 publications in 2013
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lam LKM, Reilly JP, Rux AH, Murphy SJ, Kuri-Cervantes L, Weisman AR, Ittner CAG, Pampena MB, Betts MR, Wherry EJ, Song WC, Lambris JD, Meyer NJ, Cines DB, Mangalmurti NS. Erythrocytes identify complement activation in patients with COVID-19. Am J Physiol Lung Cell Mol Physiol. 2021 08 01; 321(2):L485-L489. PMID: 34231390.
      Citations:    Fields:    Translation:HumansCells
    2. Mastellos DC, Skendros P, Lambris JD. Is complement the culprit behind COVID-19 vaccine-related adverse reactions? J Clin Invest. 2021 06 01; 131(11). PMID: 33945504.
      Citations: 7     Fields:    Translation:Humans
    3. Mastellos DC, Skendros P, Calado RT, Risitano AM, Lambris JD. Efficacy matters: broadening complement inhibition in COVID-19. Lancet Rheumatol. 2021 Feb; 3(2):e95. PMID: 33521674.
      Citations: 4     
    4. Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, Tektonidou M, Konstantinidis T, Papagoras C, Mitroulis I, Germanidis G, Lambris JD, Ritis K. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020 11 02; 130(11):6151-6157. PMID: 32759504.
      Citations: 151     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    5. Mastellos DC, Lambris JD. Response to "Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19". Clin Immunol. 2021 01; 222:108617. PMID: 33115645.
      Citations:    Fields:    Translation:Humans
    6. Mastellos DC, Pires da Silva BGP, Fonseca BAL, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol. 2020 11; 220:108598. PMID: 32961333.
      Citations: 66     Fields:    Translation:HumansCellsPHPublic Health
    7. Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD. Author Correction: Complement as a target in COVID-19? Nat Rev Immunol. 2020 07; 20(7):448. PMID: 32533108.
      Citations: 10     Fields:    
    8. Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, Huber-Lang M, Piemontese S, Assanelli A, Garlanda C, Lambris JD, Ciceri F. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 06; 215:108450. PMID: 32360516.
      Citations: 123     Fields:    Translation:HumansCellsPHPublic Health
    9. Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD. Complement as a target in COVID-19? Nat Rev Immunol. 2020 06; 20(6):343-344. PMID: 32327719.
      Citations: 178     Fields:    Translation:HumansCellsPHPublic Health